Tenders Are Invited For Pharmaceutical Products-Completion Of Non-Exclusive Discount Agreements According To § 130 A (8) Sgb V With The Active Ingredient Oxybutynin In The Daring Form Pft

Pharmaceutical Products-Completion Of Non-Exclusive Discount Agreements According To § 130 A (8) Sgb V With The Active Ingredient Oxybutynin In The Daring Form Pft. Gwq Serviceplus Ag Intends To Non -Existent Discount Agreements According To Section 130A (8) Sgb V To The Above To Close The Active Ingredient With The Start Of The Contract On May 1St, 2025. All Interested Companies Can Join This Contract At Any Time Of The Contract Period On The Same Conditions (Registration Model). The Gwq Assumes That This Procedure Does Not Fall Into The Scope Of The Antitrust Godlife Law Due To A Lack Of Selection Decision And Therefore The Possibility Of Discriminatory Access Of All Pharmaceutical Companies. The Contract Documents, The Participating Health Insurance Companies And Their Sales As Well As The Dates For The Reporting Of The Contract Must Be Viewed And Downloaded On The Gwq Serviceplus Ag Award Portal At Https://Vergestportal.Gwq-Serviceplus.De/Arzneimatic. Until The Start Of Exclusive Contracts, This Transitional Agreement Is Open To All Market Participants To Join. If The Signed Contracts / Explanation And Evidence On April 10, 2025, An Initial Report On May 1St, 2025 Can Be Realized. The Following Documents Are To Be Submitted: Signed Contract In Double Copy; Proof Of The Drug Law Approval By Means Of An Extract From The Public Part Of The Amiced Database; Signed Self -Declaration (Appendix 3). List Of Pzn (Appendix 4), Self-Declaration For The Eu Regulation (Appendix 5)